Moreover, a previous study showed that oral administration of the AhR agonist β-naphthoflavone decreased DSS-induced colitis severity and the production of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-α, IL-6, and IL-1β [47], which was consistent with our results. This evidence concerns the gene IL6 and colitis.